A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BLTE SEC filings page.
This page shows Belite Bio, Inc (BLTE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Financial Health Signals
We do not publish a peer-relative financial health score for Belite Bio, Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Belite Bio, Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Belite Bio, Inc reported a net loss of $77.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Belite Bio, Inc reported an operating loss of $84.2M against $2K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Belite Bio, Inc's EBITDA was -$84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Belite Bio, Inc reported a net loss of $77.6M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Belite Bio, Inc earned -$2.31 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Belite Bio, Inc recorded an outflow of $37.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Belite Bio, Inc held $352.9M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Belite Bio, Inc's ROE was -10.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 14.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Belite Bio, Inc invested $45.4M in research and development in fiscal year 2025. This represents an increase of 51.6% from the prior year.
Belite Bio, Inc invested $71K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 38.8% from the prior year.
Not reported for fiscal year 2025.
BLTE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| R&D Expenses | $45.4M+51.6% | $29.9M+20.5% | $24.8M+180.1% | $8.9M+19.5% | $7.4M+101.2% | $3.7M |
| SG&A Expenses | $38.8M+286.1% | $10.1M+47.4% | $6.8M+72.7% | $4.0M+66.2% | $2.4M+15.7% | $2.1M |
| Operating Income | -$84.2Mn/m | -$40.0Mn/m | -$31.7Mn/m | -$12.8Mn/m | -$9.8Mn/m | -$5.7M |
| EBITDA | -$84.0Mn/m | -$39.8Mn/m | -$31.5Mn/m | -$12.8Mn/m | -$9.8Mn/m | -$5.7M |
| Interest Expense | $2K-90.0% | $20K-20.0% | $25K+56.3% | $16K | N/A | $21K |
| Income Tax | $0-100.0% | $6K-33.3% | $9K | N/A | N/A | $1K |
| Net Income | -$77.6Mn/m | -$36.1Mn/m | -$31.6Mn/m | -$12.6Mn/m | -$9.7Mn/m | -$5.8M |
| EPS (Basic) | -$2.31n/m | -$1.18n/m | -$1.19n/m | -$0.63 | -$1.01n/m | -$0.65 |
| EPS (Diluted) | -$2.31n/m | -$1.18n/m | -$1.19n/m | -$0.63 | -$1.01n/m | -$0.65 |
| Diluted Shares (Avg) | 34M+9.8% | 31M+14.8% | 27M+33.1% | 20M | 10M+8.9% | 9M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
BLTE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Total Assets | $780.6M+413.1% | $152.1M+60.7% | $94.6M+113.8% | $44.3M+141.3% | $18.3M | N/A |
| Current Assets | $494.3M+236.1% | $147.1M+63.5% | $89.9M+110.1% | $42.8M+145.6% | $17.4M | N/A |
| Cash & Equivalents | $352.9M+1014.2% | $31.7M-64.1% | $88.2M+109.5% | $42.1M+142.7% | $17.3M-32.3% | $25.6M |
| Short-Term Investments | $139.5M+2966.4% | $4.5Mn/m | $0n/m | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $10.1M+59.6% | $6.3M+49.9% | $4.2M+51.9% | $2.8M-91.7% | $33.4M | N/A |
| Current Liabilities | $9.9M+63.3% | $6.0M+66.5% | $3.6M+72.7% | $2.1M+28.7% | $1.6M | N/A |
| Non-Current Liabilities | $188K-28.0% | $261K-54.8% | $578K-13.5% | $668K-97.9% | $31.8M | N/A |
| Total Equity | $770.5M+428.4% | $145.8M+61.3% | $90.4M+117.9% | $41.5Mn/m | -$15.1Mn/m | -$7.0M |
| Retained Earnings | -$185.3Mn/m | -$107.6Mn/m | -$71.5Mn/m | -$39.9Mn/m | -$27.2Mn/m | -$17.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BLTE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$37.0Mn/m | -$29.2Mn/m | -$29.8Mn/m | -$11.5Mn/m | -$7.5Mn/m | -$4.4M |
| Depreciation & Amortization | $184K+9.5% | $168K+20.9% | $139K+117.2% | $64K+113.3% | $30K+76.5% | $17K |
| Stock-Based Compensation | $38.9M+333.1% | $9.0M+135.1% | $3.8M+157.8% | $1.5M-3.1% | $1.5M+12.3% | $1.4M |
| Capital Expenditures | $71K-38.8% | $116K+84.1% | $63K-84.0% | $394K+432.4% | $74K | N/A |
| Free Cash Flow | -$37.1Mn/m | -$29.4Mn/m | -$29.9Mn/m | -$11.9Mn/m | -$7.5M | N/A |
| Investing Cash Flow | -$305.1Mn/m | -$110.6Mn/m | -$63Kn/m | -$394Kn/m | -$56Kn/m | -$20K |
| Financing Cash Flow | $663.2M+693.4% | $83.6M+10.1% | $76.0M+105.5% | $37.0Mn/m | -$583K-102.1% | $28.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BLTE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F |
|---|---|---|---|---|---|---|
| Return on Equity | -10.1%+14.7pp | -24.8%+10.2pp | -35.0%-4.5pp | -30.5% | N/A | N/A |
| Return on Assets | -9.9%+13.8pp | -23.8%+9.7pp | -33.4%-4.8pp | -28.6%+24.1pp | -52.7% | N/A |
| Current Ratio | 50.02+25.7x | 24.31-0.4x | 24.76+4.4x | 20.35+9.7x | 10.66 | N/A |
| Liabilities-to-Equity | 0.010.0x | 0.040.0x | 0.050.0x | 0.07 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Belite Bio, Inc BLTE | FY2025 | N/A | -$77.6M | N/A | $5.2B | — |
| Arrowhead Research Corporation ARWR | FY2026 | $450.8M | -$724.2M | N/A | $5.8B | 73/100 |
| Veradermics, Incorporated MANE | FY2025 | N/A | -$70.0M | N/A | $5.0B | — |
| Dianthus Therapeutics, Inc. DNTH | FY2025 | $2.0M | -$162.3M | N/A | $4.8B | 56/100 |
| Scholar Rock Holding Corporation SRRK | FY2025 | $0 | -$377.9M | N/A | $5.9B | — |
| Erasca, Inc. ERAS | FY2025 | N/A | -$124.5M | N/A | $4.8B | — |
Where Belite Bio, Inc Ranks
Frequently Asked Questions
No, Belite Bio, Inc (BLTE) reported a net loss of $77.6M in fiscal year 2025.
Belite Bio, Inc (BLTE) had EBITDA of -$84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Belite Bio, Inc (BLTE) has a return on equity of -10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Belite Bio, Inc (BLTE) recorded an outflow of $37.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Belite Bio, Inc (BLTE) recorded an outflow of $37.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Belite Bio, Inc (BLTE) had $780.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Belite Bio, Inc (BLTE) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Belite Bio, Inc (BLTE) invested $45.4M in research and development during fiscal year 2025.
Belite Bio, Inc (BLTE) had a current ratio of 50.02 as of fiscal year 2025, which is generally considered healthy.
Belite Bio, Inc (BLTE) had a liabilities-to-equity ratio of 0.01 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Belite Bio, Inc (BLTE) had a return on assets of -9.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Belite Bio, Inc (BLTE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Belite Bio, Inc (BLTE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $5.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Belite Bio, Inc (BLTE) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Belite Bio, Inc (BLTE) reported a net loss of $77.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Belite Bio, Inc (BLTE) reported an operating loss of $84.2M against $2K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.